Trial | Enrollment | No. of patients | Surgery | Eligibility | Randomization | Loco-regional recurrence | Survival |
GOG-994 | 1987–1995 | 392 | TH-BSO+LND | Stages IB/C; stage II (occult) | EBRT vs NAT | 2 years: 3% vs 12% (p=0.007) | 4 years: 86% vs 92% (p=0.0557) |
PORTEC-15 | 1990–1997 | 714 | TH-BSO | Stages IB G2-3; stages IC G1-2 | EBRT vs NAT | 5 years: 4% vs 14% (p<0.001) | 5 years: 85% vs 81% (p=0.31) |
Swedish7 | 1997–2008 | 527 | TH-BSO | Stage I intermediate risk | VBT vs VBT+EBRT | 5 years: 5% vs 1.5% (p=0.013) | 5 years: 90% vs 89% (p=0.55) |
ASTEC/EN.56 | 1996–2008 | 905 | TH-BSO±LND | Stages IA/B G3; IC; stage II; serous/CC | EBRT vs NAT | 5 years: 6% vs 3% (p=0.02) | 5 years: 84% vs 84% (p=0.98) |
PORTEC-28 | 2002–2006 | 427 | TH-BSO | Age >60 and stage IB G3 or stages IC G1-2; stage IIA | EBRT vs VBT | 5 years: 5% vs 2% (p=0.17) | 5 years: 85% vs 80% (p=0.57) |
LND; lymph node dissection G; grade; LND; lymph node G; grade; EBRT, external beam radiation therapy; GOG, Gynaecologic Oncology Group; NAT, no adjuvant treayment; PORTEC, Post Operative Radiation Therapy for Endometrial Carcinoma; TH-BSO, total hysterectomy and bilateral salpingo-oophorectomy; VBT, vaginal brachy therapy.